Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Preventing rejection and ensuring survival of grafts

Project description

New model to reduce organ rejection in transplant recipients

Each year, 130 000 patients receive transplants worldwide. The success of organ transplantation relies on the lifelong use of immunosuppressive drugs to prevent rejection. However, these drugs can have significant side effects, including opportunistic infections and cancers. Recent research indicates that the bacteria Listeria monocytogenes can render infected cells resistant to T-cell-mediated killing. The ERC-funded PRESERVE project aims to protect grafted cells from T-cell-mediated killing, thereby reducing organ rejection. It will lay the groundwork for patent filing and the establishment of a robust business model for further development and clinical translation. This approach has the potential to decrease the need for immunosuppressive therapy in transplant recipients.

Objective

The success of organ transplantation depends on the lifelong use of immunosuppressive drugs to prevent rejection of the donor cells by the recipients immune system. These immunosuppressive drugs have several limitations, most notably major side effects, namely opportunistic infections and cancers. We have recently shown that the bacterial pathogen Listeria monocytogenes (Lm) induces the resistance of infected cells to T-cell mediated killing. This project aims to protect grafted cells from T cell-mediated killing and thereby mitigate organ rejection. This will lay the groundwork for patent filing and the establishment of a robust business model to ensure further development and clinical translation. This innovative approach is expected to reduce the need for immunosuppressive therapy in transplant recipients, thereby improving outcomes and quality of life for the 130,000 patients who receive transplants worldwide each year. This proof-of-concept project is based on our recently published study (Maudet et al, Nature 2022) supported by the ERC Invadis grant.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

INSTITUT PASTEUR
Net EU contribution
€ 150 000,00
Address
RUE DU DOCTEUR ROUX 25-28
75724 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)